OostNL

AMT Medical B.V., established in 2015 and located in Ede, the Netherlands, specializes in the development of innovative medical devices for heart bypass surgery. The company's flagship product, the AMT Heart Bypass System, utilizes a minimal invasive technique known as the ELANA bypass, which was invented by neurosurgeon Prof. Dr. C.A.F. Tulleken and his research team. This advanced technology aims to enhance traditional heart bypass procedures by making them faster, safer, and less invasive, thereby improving patient outcomes and reducing complications. AMT Medical has completed the full development of its product and the production process, with all pre-clinical trials successfully concluded. The company is also preparing to initiate a clinical multi-center trial to further validate the technology's efficacy.

Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands, established in 2011 as a spin-out from Philips Healthcare. The company focuses on developing innovative in vivo chemistry to enhance the effectiveness of cancer therapies and to facilitate novel companion diagnostics. Operating from the Radboud University Medical Center in Nijmegen, Tagworks specializes in antibody-based imaging and therapy technologies. Its proprietary approach allows for the selective chemical manipulation of tagged antibodies in vivo, which improves the efficacy of established methods like radioimmuno-imaging and antibody-drug conjugates. This technology enables medical professionals to conduct imaging with significantly reduced radiation exposure for patients.

Prolira BV is a medical technology company based in Utrecht, the Netherlands, founded in 2015. It specializes in developing DeltaScan, an innovative EEG-based medical device designed for the early detection of delirium, a form of acute brain failure. The DeltaScan system comprises a single-use electrode patch known as the DeltaScan Patch and a hardware/software module called the DeltaScan Monitor, which analyzes brain activity to support clinical decision-making. Prolira is dedicated to enabling timely and effective treatment for acute encephalopathy and delirium, conditions that affect approximately 20 million patients annually in hospitals across the European Union and the United States. By providing the first EEG bedside device with a validated proprietary algorithm, Prolira aims to help clinicians optimize patient recovery, ultimately reducing long-term cognitive impairment and hospital costs.

ATRO Medical B.V., based in Nijmegen, the Netherlands, specializes in the development of anatomically shaped polymer meniscus implants, specifically the Trammpolin. This innovative prosthesis is designed to replace damaged menisci, restoring their protective function by acting as a joint spacer and shock absorber. The Trammpolin mimics the natural meniscus, facilitating adequate load distribution within the knee joint, which can provide significant relief for osteoarthritis patients suffering from severe pain. ATRO Medical emerged as a spin-out from DSM and Radboudumc, leveraging expertise from a public-private collaboration initiated in 2010 that involved various universities, private companies, and support from the Dutch government. This collaborative effort has been instrumental in the design and development of the Trammpolin prototype.

ScreenPoint Medical B.V. is a company based in Nijmegen, the Netherlands, specializing in the development of artificial intelligence software designed to assist radiologists in interpreting digital breast tomosynthesis (DBT) and mammography exams. Founded in 2014, ScreenPoint focuses on creating deep learning and image analysis technologies that enhance the accuracy and consistency of breast cancer detection. By leveraging advanced machine learning techniques alongside extensive, well-curated digital image databases, the company aims to improve the diagnostic process for breast cancer, thereby enabling earlier detection and reducing unnecessary patient recalls. Their flagship product, Transpara, exemplifies this commitment to enhancing clinical outcomes in mammography through innovative technology.

InteRNA Technologies B.V. is a biotechnology company focused on developing microRNA (miRNA)-based therapeutics for cancer treatment. Founded in 2006 and headquartered in Nijmegen, the Netherlands, with a research and development center in Utrecht, the company leverages its proprietary technology to discover and validate miRNA sequences that can target multiple signaling pathways involved in cancer initiation, progression, and metastasis. By addressing previously undruggable targets, InteRNA aims to enhance the efficacy of existing cancer therapies and reduce the development of drug resistance. The company employs advanced bioinformatics and massively parallel sequencing techniques to analyze miRNA functions, paving the way for innovative treatment options in oncology.

Eurekite BV, based in Enschede, the Netherlands, specializes in the manufacture of flexible ceramic materials. Established in May 2015 as a spin-off from the University of Twente, the company focuses on the development and commercialization of its innovative technology, known as Flexiramics®. This technology emerged from the Inorganic Materials Science Group of the MESA + Institute for Nanotechnology, led by Professor Andre ten Elshof. Eurekite combines expertise in formulation chemistry, production technology, and composite development, with its disruptive materials attracting investment from prominent venture capital firms.

Pepscope BV is a biotechnology company based in Nijmegen, the Netherlands, specializing in the development of innovative protein kinase activity profiling technologies. Founded in 2012, the company focuses on creating solutions that enhance the discovery and development of novel kinase inhibitors and other therapeutic compounds. Pepscope offers its flagship product, QuantaKinome, to the pharmaceutical industry and academic researchers, facilitating the identification of new applications for existing compounds and aiding in the selection of optimal therapies tailored to individual patients. In addition to kinase profiling assays, Pepscope provides advanced proteomics services, utilizing microarray and mass spectrometry techniques to deliver reproducible results and robust conclusions for research and diagnostics.

Prolira BV is a medical technology company based in Utrecht, the Netherlands, founded in 2015. It specializes in developing DeltaScan, an innovative EEG-based medical device designed for the early detection of delirium, a form of acute brain failure. The DeltaScan system comprises a single-use electrode patch known as the DeltaScan Patch and a hardware/software module called the DeltaScan Monitor, which analyzes brain activity to support clinical decision-making. Prolira is dedicated to enabling timely and effective treatment for acute encephalopathy and delirium, conditions that affect approximately 20 million patients annually in hospitals across the European Union and the United States. By providing the first EEG bedside device with a validated proprietary algorithm, Prolira aims to help clinicians optimize patient recovery, ultimately reducing long-term cognitive impairment and hospital costs.

Plasmacure, headquartered in Eindhoven, Netherlands, is a medical technology company focused on developing innovative solutions for chronic wound healing, with a particular emphasis on diabetic foot wounds. The company's core product is a patented cold plasma solution designed to kill bacteria, stimulate cell proliferation, and improve microcirculation, thereby reducing the risk of amputation and enhancing patients' quality of life.

SuperBuddy is an on-demand grocery delivery service based in the Netherlands. The company operates an online marketplace that allows users to shop for groceries from local stores. By connecting customers with personal shoppers, SuperBuddy facilitates a tailored shopping experience where users can specify their preferences. The platform ensures timely delivery, typically within a two-hour window, enabling customers to conveniently receive their selected items at their doorstep.